User:Kurt Corsbie/Sandbox 1

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 8: Line 8:
<scene name='72/726409/Overview/5'>mGlu<sub>5</sub></scene> is seen as a [https://en.wikipedia.org/wiki/Protein_dimer homodimer] ''in vivo,'' with each subunit being comprised of three domains: extracellular, trans-membrane and cysteine-rich. mGlu<sub>5</sub> is centered on the trans-membrane domain, comprised of seven α-helices all roughly parallel.<ref name="Primary">PMID: 25042998 </ref> Also displayed is Intracellular Loop (ICL) 1 which forms a short α-helix and interacts directly with a trans-membrane helix to stabilize mGlu<sub>5</sub>’s conformation. Additionally, ICL3 and Extracellular Loops (ECL) 1 and 3 all lack secondary structure, and ECL2 interacts with trans-membrane (TM) helices 1, 2, and 3 as well as ECL 1,again helping to stabilize the protein’s overall conformation.<ref name="Primary">PMID: 25042998 </ref>
<scene name='72/726409/Overview/5'>mGlu<sub>5</sub></scene> is seen as a [https://en.wikipedia.org/wiki/Protein_dimer homodimer] ''in vivo,'' with each subunit being comprised of three domains: extracellular, trans-membrane and cysteine-rich. mGlu<sub>5</sub> is centered on the trans-membrane domain, comprised of seven α-helices all roughly parallel.<ref name="Primary">PMID: 25042998 </ref> Also displayed is Intracellular Loop (ICL) 1 which forms a short α-helix and interacts directly with a trans-membrane helix to stabilize mGlu<sub>5</sub>’s conformation. Additionally, ICL3 and Extracellular Loops (ECL) 1 and 3 all lack secondary structure, and ECL2 interacts with trans-membrane (TM) helices 1, 2, and 3 as well as ECL 1,again helping to stabilize the protein’s overall conformation.<ref name="Primary">PMID: 25042998 </ref>
===Key Interactions===
===Key Interactions===
-
A number of intramolecular interactions within the trans-membrane domain stabilize the inactive conformation of mGlu<sub>5</sub>, as demonstrated by <scene name='72/726409/Overview/5'>mGlu<sub>5</sub></scene> being represented in the inactivate state. While in the inactive state, glutamate binding to mGlu<sub>5</sub> triggers a conformational change that leads to mGlu<sub>5</sub> to be in the active state and hence triggers the aforementioned [https://en.wikipedia.org/wiki/Gq_alpha_subunit G<sub>q</sub> pathway]. The first of these interactions is an ionic interaction, termed the <scene name='72/726409/Ionic_lock2/2'>Ionic Lock</scene>, between Lysine 665 of TM3 and Glutamate 770 of TM6. Evidence for the importance of this interaction came through a kinetic study of mutant proteins where both residues were separately substituted with alanine, resulting in constitutive activity of the GPCR and its coupled pathway.<ref name="Primary">PMID: 25042998 </ref> A second critical interaction that stabilizes the inactive conformer is a <scene name='72/726409/Hydrogen_bond_614-668/2'>Hydrogen Bond </scene> between Serine 614 of ICL1 and Arginine 668 of TM3. Similarly, when Serine 614 was mutated to alanine, high levels of activity were seen in the mutant GPCR.<ref name="Primary">PMID: 25042998 </ref> A <scene name='72/726404/Scene_6/8'>Disulfide Bond </scene> between Cysteine 644 of TM3 and Cysteine 733 of <scene name='72/726409/Mavoglurant_overview2/3'>ECL2</scene> is critical at anchoring ECL2 and is highly conserved across Class C GPCR’s.<ref name="Primary">PMID: 25042998 </ref> The ECL2's presence combined with the helical bundle of the trans-membrane domain creates a <scene name='72/726409/Electrogradient2/9'>Binding Cap</scene> that restricts entrance to the allosteric binding site within the seven trans-membrane α-helices. This restricted entrance has no effect on the natural ligand, glutamate, as it binds to the extracellular domain, but this entrance dictates potential drug targets that act through allosteric modulation.<ref name="Primary">PMID: 25042998 </ref>
+
A number of intramolecular interactions within the trans-membrane domain stabilize the inactive conformation of mGlu<sub>5</sub>, as demonstrated by <scene name='72/726409/Overview/5'>mGlu<sub>5</sub></scene> being represented in the inactivate state. While in the inactive state, glutamate binding to mGlu<sub>5</sub> triggers a conformational change that leads to mGlu<sub>5</sub> to be in the active state and hence triggers the aforementioned [https://en.wikipedia.org/wiki/Gq_alpha_subunit G<sub>q</sub> pathway]. The first of these interactions is an ionic interaction, termed the <scene name='72/726409/Ionic_lock2/2'>Ionic Lock</scene>, between Lysine 665 of TM3 and Glutamate 770 of TM6. Evidence for the importance of this interaction came through a kinetic study of mutant proteins where both residues were separately substituted with alanine, resulting in constitutive activity of the GPCR and its coupled pathway.<ref name="Primary">PMID: 25042998 </ref> A second critical interaction that stabilizes the inactive conformer is a <scene name='72/726409/Hydrogen_bond_614-668/2'>Hydrogen Bond </scene> between Serine 614 of ICL1 and Arginine 668 of TM3. Similarly, when Serine 614 was substituted with alanine, high levels of activity were seen in the mutant GPCR.<ref name="Primary">PMID: 25042998 </ref> A <scene name='72/726404/Scene_6/8'>Disulfide Bond </scene> between Cysteine 644 of TM3 and Cysteine 733 of <scene name='72/726409/Mavoglurant_overview2/3'>ECL2</scene> is critical at anchoring ECL2 and is highly conserved across Class C GPCR’s.<ref name="Primary">PMID: 25042998 </ref> The ECL2's presence combined with the helical bundle of the trans-membrane domain creates a <scene name='72/726409/Electrogradient2/9'>Binding Cap</scene> that restricts entrance to the allosteric binding site within the seven trans-membrane α-helices. This restricted entrance has no effect on the natural ligand, glutamate, as it binds to the extracellular domain, but this entrance dictates potential drug targets that act through allosteric modulation.<ref name="Primary">PMID: 25042998 </ref>
== Clinical Relevance ==
== Clinical Relevance ==
===Role in Diseases===
===Role in Diseases===
Line 15: Line 15:
===Interactions with a Negative Allosteric Modulator===
===Interactions with a Negative Allosteric Modulator===
The structure of mGlu<sub>5</sub> bound to the NAM [https://en.wikipedia.org/wiki/Mavoglurant Mavoglurant] demonstrates how protein activity is decreased through drug interactions.
The structure of mGlu<sub>5</sub> bound to the NAM [https://en.wikipedia.org/wiki/Mavoglurant Mavoglurant] demonstrates how protein activity is decreased through drug interactions.
-
<scene name='72/726404/Scene_7/5'>Mavoglurant</scene> binds within the allosteric binding site in the core of the seven trans-membrane α-helices, having passed through the restricted entrance formed by the <scene name='72/726409/Mavoglurant_overview2/3'>ECL2</scene>. Bound Mavoglurant forms multiple interactions with the protein that further stabilize the inactive conformation.
+
<scene name='72/726404/Scene_7/6'>Mavoglurant</scene> binds within the allosteric binding site in the core of the seven trans-membrane α-helices, having passed through the restricted entrance formed by the <scene name='72/726409/Mavoglurant_overview2/3'>ECL2</scene>. Bound Mavoglurant forms multiple interactions with the protein that further stabilize the inactive conformation.
The bicyclic ring system of the drug is surrounded by a pocket of mainly hydrophobic residues including Val 806, Met 802, Phe 788, Trp 785, Leu 744, Ile 651, Pro 655, and Asn 747 (Figure 1).<ref name="Primary">PMID: 25042998 </ref> The carbamate tail of Mavoglurant forms a hydrogen bond through its carbonyl oxygen to the amide side-chain of Asparagine 747 of TM4 (Figure 2). A hydroxyl group similarly forms hydrogen bonds to mGlu<sub>5</sub>, specifically at two serine residues (S805 and S809) of TM7. These residues form a hydrogen bonding network to other residues through their main chain atoms and a coordinated water molecule (omitted for clarity) (Figure 3). The interactions between Mavoglurant and mGlu<sub>5</sub> involve TM helices that were not previously stabilized by any strong interactions, introducing a new level of stability that favors the inactive conformation of the protein and hence decreases the overall activity of mGlu<sub>5</sub>.<ref name="Primary">PMID: 25042998 </ref>
The bicyclic ring system of the drug is surrounded by a pocket of mainly hydrophobic residues including Val 806, Met 802, Phe 788, Trp 785, Leu 744, Ile 651, Pro 655, and Asn 747 (Figure 1).<ref name="Primary">PMID: 25042998 </ref> The carbamate tail of Mavoglurant forms a hydrogen bond through its carbonyl oxygen to the amide side-chain of Asparagine 747 of TM4 (Figure 2). A hydroxyl group similarly forms hydrogen bonds to mGlu<sub>5</sub>, specifically at two serine residues (S805 and S809) of TM7. These residues form a hydrogen bonding network to other residues through their main chain atoms and a coordinated water molecule (omitted for clarity) (Figure 3). The interactions between Mavoglurant and mGlu<sub>5</sub> involve TM helices that were not previously stabilized by any strong interactions, introducing a new level of stability that favors the inactive conformation of the protein and hence decreases the overall activity of mGlu<sub>5</sub>.<ref name="Primary">PMID: 25042998 </ref>

Revision as of 02:05, 17 April 2016

metabotropic Glutamate Receptor 5 PDB:4oo9

Drag the structure with the mouse to rotate

References

  1. Vassilatis DK, Hohmann JG, Zeng H, Li F, Ranchalis JE, Mortrud MT, Brown A, Rodriguez SS, Weller JR, Wright AC, Bergmann JE, Gaitanaris GA. The G protein-coupled receptor repertoires of human and mouse. Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4903-8. Epub 2003 Apr 4. PMID:12679517 doi:http://dx.doi.org/10.1073/pnas.0230374100
  2. 2.0 2.1 Venkatakrishnan AJ, Deupi X, Lebon G, Tate CG, Schertler GF, Babu MM. Molecular signatures of G-protein-coupled receptors. Nature. 2013 Feb 14;494(7436):185-94. doi: 10.1038/nature11896. PMID:23407534 doi:http://dx.doi.org/10.1038/nature11896
  3. Pin JP, Galvez T, Prezeau L. Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors. Pharmacol Ther. 2003 Jun;98(3):325-54. PMID:12782243
  4. 4.0 4.1 4.2 4.3 4.4 4.5 4.6 4.7 4.8 4.9 Dore AS, Okrasa K, Patel JC, Serrano-Vega M, Bennett K, Cooke RM, Errey JC, Jazayeri A, Khan S, Tehan B, Weir M, Wiggin GR, Marshall FH. Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain. Nature. 2014 Jul 31;511(7511):557-62. doi: 10.1038/nature13396. Epub 2014 Jul 6. PMID:25042998 doi:http://dx.doi.org/10.1038/nature13396
  5. Shigemoto R, Nomura S, Ohishi H, Sugihara H, Nakanishi S, Mizuno N. Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain. Neurosci Lett. 1993 Nov 26;163(1):53-7. PMID:8295733
  6. 6.0 6.1 Li G, Jorgensen M, Campbell BM. Metabotropic glutamate receptor 5-negative allosteric modulators for the treatment of psychiatric and neurological disorders (2009-July 2013). Pharm Pat Anal. 2013 Nov;2(6):767-802. doi: 10.4155/ppa.13.58. PMID:24237242 doi:http://dx.doi.org/10.4155/ppa.13.58
  7. Fuxe K, Borroto-Escuela DO. Basimglurant for treatment of major depressive disorder: a novel negative allosteric modulator of metabotropic glutamate receptor 5. Expert Opin Investig Drugs. 2015;24(9):1247-60. doi:, 10.1517/13543784.2015.1074175. Epub 2015 Jul 29. PMID:26219727 doi:http://dx.doi.org/10.1517/13543784.2015.1074175
  8. Domin H, Szewczyk B, Wozniak M, Wawrzak-Wlecial A, Smialowska M. Antidepressant-like effect of the mGluR5 antagonist MTEP in an astroglial degeneration model of depression. Behav Brain Res. 2014 Oct 15;273:23-33. doi: 10.1016/j.bbr.2014.07.019. Epub 2014, Jul 18. PMID:25043733 doi:http://dx.doi.org/10.1016/j.bbr.2014.07.019

Proteopedia Page Contributors and Editors (what is this?)

Kurt Corsbie

Personal tools